PLX5568-Plexxikon
PLX5568-Plexxikon Wait
PLX5568 a RAF kinases inhibitor, an oral pill, does slow down cyst development but also causes both kidney and liver fibrosis. More research is needed. PLEXXIKON and Roche have entered into research together to try to develop this drug.
Conclusion: PLX5568 attenuated ↓ cyst enlargement in vitro and in a rat model of ADPKD without improving kidney function, presumably due to increased renal fibrosis. These data suggest that effective therapies for the treatment of ADPKD will need to target fibrosis as well as the growth of cysts.
There is now some neuropathology research with Plexxikon is now in research trials for glioblastoma, improvement of cognitive functioning following radiation, Alzheimer's disease, melanoma and more.
